Capital Analysts LLC Acquires New Position in Clovis Oncology, Inc. (CLVS)
Capital Analysts LLC acquired a new position in Clovis Oncology, Inc. (NASDAQ:CLVS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,350 shares of the biopharmaceutical company’s stock, valued at approximately $111,000.
Other large investors have also recently made changes to their positions in the company. Phocas Financial Corp. bought a new position in Clovis Oncology in the second quarter worth approximately $112,000. Advisors Asset Management Inc. grew its stake in Clovis Oncology by 160.7% in the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 1,168 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 100 shares in the last quarter. Legato Capital Management LLC bought a new position in Clovis Oncology in the second quarter worth approximately $220,000. Finally, Prudential Financial Inc. bought a new position in Clovis Oncology in the first quarter worth approximately $242,000. 98.53% of the stock is currently owned by institutional investors.
Several brokerages recently issued reports on CLVS. BidaskClub cut Clovis Oncology from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 9th. Morgan Stanley reissued an “overweight” rating and issued a $93.00 price objective on shares of Clovis Oncology in a research note on Thursday, August 10th. Stifel Nicolaus reissued a “buy” rating and issued a $125.00 price objective on shares of Clovis Oncology in a research note on Friday, November 3rd. Bank of America Corporation reissued a “buy” rating on shares of Clovis Oncology in a research note on Thursday, August 3rd. Finally, Leerink Swann lowered their target price on Clovis Oncology to $107.00 and set an “outperform” rating for the company in a report on Friday, August 18th. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Clovis Oncology currently has an average rating of “Buy” and an average target price of $87.15.
Shares of Clovis Oncology, Inc. (CLVS) traded down $0.26 on Monday, hitting $66.95. The stock had a trading volume of 1,039,300 shares, compared to its average volume of 1,876,103. Clovis Oncology, Inc. has a 12-month low of $31.64 and a 12-month high of $99.45. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. The business had revenue of $16.81 million for the quarter, compared to analysts’ expectations of $21.12 million. During the same quarter in the prior year, the company posted ($1.70) EPS. analysts forecast that Clovis Oncology, Inc. will post -7.31 earnings per share for the current year.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $69.50, for a total transaction of $208,500.00. Following the completion of the sale, the insider now owns 191,583 shares in the company, valued at approximately $13,315,018.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 9,000 shares of company stock valued at $672,270. Company insiders own 12.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/capital-analysts-llc-acquires-new-position-in-clovis-oncology-inc-clvs.html.
Clovis Oncology Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.